These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 19814676)

  • 1. Update on thalassemia treatment in Taiwan, including bone marrow transplantation, chelation therapy, and cardiomyopathy treatment effects.
    Peng CT; Chang JS; Wang LY; Chiou SS; Hsiao CC; Wang SC; Hung GY; Wu KH
    Hemoglobin; 2009; 33(5):304-11. PubMed ID: 19814676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac IRON and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators.
    Kolnagou A; Kontoghiorghes GJ
    Hemoglobin; 2006; 30(2):239-49. PubMed ID: 16798649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies.
    Maggio A; Vitrano A; Capra M; Cuccia L; Gagliardotto F; Filosa A; Magnano C; Rizzo M; Caruso V; Gerardi C; Argento C; Campisi S; Cantella F; Commendatore F; D'Ascola DG; Fidone C; Ciancio A; Galati MC; Giuffrida G; Cingari R; Giugno G; Lombardo T; Prossomariti L; Malizia R; Meo A; Roccamo G; Romeo MA; Violi P; Cianciulli P; Rigano P
    Blood Cells Mol Dis; 2009; 42(3):247-51. PubMed ID: 19233692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new era in iron chelation therapy: the design of optimal, individually adjusted iron chelation therapies for the complete removal of iron overload in thalassemia and other chronically transfused patients.
    Kontoghiorghes GJ
    Hemoglobin; 2009; 33(5):332-8. PubMed ID: 19814679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A practical chelation protocol based on stratification of thalassemic patients by serum ferritin and magnetic resonance imaging cardiac T2*.
    Ha SY; Mok AS; Chu WC; Raskalkar DD; Cheuk DK; Chiang AK; Ho MH; Chan GC
    Hemoglobin; 2009; 33(5):323-31. PubMed ID: 19814678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent developments in iron chelation therapy.
    Cario H; Janka-Schaub G; Janssen G; Jarisch A; Strauss G; Kohne E
    Klin Padiatr; 2007; 219(3):158-65. PubMed ID: 17525910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coenzyme Q10 levels in β-thalassemia and its association with ferritin levels and chelation therapy.
    Karakukcu C; Karakukcu M; Unal E; Patiroglu T; Ozdemir MA; Torun YA; Tang PH
    Hemoglobin; 2012; 36(3):219-29. PubMed ID: 22483337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients.
    Balocco M; Carrara P; Pinto V; Forni GL
    Am J Hematol; 2010 Jun; 85(6):460-1. PubMed ID: 20513129
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.
    Saliba AN; El Rassi F; Taher AT
    Expert Rev Hematol; 2016; 9(2):151-68. PubMed ID: 26613264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Objectives and mechanism of iron chelation therapy.
    Hershko C; Link G; Konijn AM; Cabantchik ZI
    Ann N Y Acad Sci; 2005; 1054():124-35. PubMed ID: 16339658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry.
    Fischer R; Piga A; Harmatz P; Nielsen P
    Ann N Y Acad Sci; 2005; 1054():350-7. PubMed ID: 16339683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of chelation therapy on cardiac function improvement in thalassemia patients: literature review and the Taiwanese experience.
    Peng CT; Tsai CH; Wu KH
    Hemoglobin; 2008; 32(1-2):49-62. PubMed ID: 18274983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction.
    Tanner MA; Galanello R; Dessi C; Smith GC; Westwood MA; Agus A; Pibiri M; Nair SV; Walker JM; Pennell DJ
    J Cardiovasc Magn Reson; 2008 Feb; 10(1):12. PubMed ID: 18298856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of combined deferiprone and deferoxamine chelation therapy on iron load indices in beta-thalassemia.
    Tsironi M; Assimakopoulos G; Polonofi K; Rigaki K; Aessopos A
    Hemoglobin; 2008; 32(1-2):29-34. PubMed ID: 18274980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in the prevention and treatment are changing thalassemia from a fatal to a chronic disease. experience from a Cyprus model and its use as a paradigm for future applications.
    Kolnagou A; Kontoghiorghes GJ
    Hemoglobin; 2009; 33(5):287-95. PubMed ID: 19814674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox.
    Kontoghiorghes GJ
    Hemoglobin; 2008; 32(1-2):1-15. PubMed ID: 18274978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxamine combination protocol.
    Kolnagou A; Yazman D; Economides C; Eracleous E; Kontoghiorghes GJ
    Hemoglobin; 2009; 33(5):312-22. PubMed ID: 19814677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone.
    Lai ME; Grady RW; Vacquer S; Pepe A; Carta MP; Bina P; Sau F; Cianciulli P; Maggio A; Galanello R; Farci P
    Blood Cells Mol Dis; 2010 Aug; 45(2):136-9. PubMed ID: 20678715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential alternating deferiprone and deferoxamine treatment compared to deferiprone monotherapy: main findings and clinical follow-up of a large multicenter randomized clinical trial in -thalassemia major patients.
    Pantalone GR; Maggio A; Vitrano A; Capra M; Cuccia L; Gagliardotto F; Filosa A; Romeo MA; Magnano C; Caruso V; Argento C; Gerardi C; Campisi S; Violi P; Malizia R; Cianciulli P; Rizzo M; D'Ascola DG; Quota A; Prossomariti L; Fidone C; Rigano P; Pepe A; D'Amico G; Morabito A; Gluud C
    Hemoglobin; 2011; 35(3):206-16. PubMed ID: 21599433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload.
    Hagag AA; Hamam MA; Taha OA; Hazaa SM
    Infect Disord Drug Targets; 2015; 15(2):98-105. PubMed ID: 26205801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.